PHARVARIS N.V. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 20.66 USD | +1.52% |
|
-2.41% | -26.35% |
| May. 09 | Wedbush Adjusts Pharvaris' Price Target to $31 From $35, Maintains Outperform Rating | MT |
| May. 08 | Pharvaris N.V. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Exceptional extension!
Take advantage of the offer
* See conditions on site
| Sales 2024 * | - | Sales 2025 * | - | Capitalization | 1.02B 1.11B |
|---|---|---|---|---|---|
| Net income 2024 * | -122M -132M | Net income 2025 * | -139M -151M | EV / Sales 2024 * | - |
| Net cash position 2024 * | 269M 292M | Net cash position 2025 * | 132M 143M | EV / Sales 2025 * | - |
| P/E ratio 2024 * |
-7.91
x | P/E ratio 2025 * |
-7.57
x | Employees | 82 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 61% |
More Fundamentals
* Assessed data
More news
Latest transcript on Pharvaris N.V.
More recommendations
More press releases
| 1 day | +1.52% | ||
| 1 week | -2.41% | ||
| Current month | -15.98% | ||
| 1 month | +7.83% | ||
| 3 months | -23.82% | ||
| 6 months | +35.92% | ||
| Current year | -26.35% |
1 week
19.19
24.11
1 month
17.5725.50
Current year
17.5733.00
1 year
8.2033.00
3 years
1.7733.00
5 years
1.7742.86
10 years
1.7742.86
| Managers | Title | Age | Since |
|---|---|---|---|
Anne Lesage
FOU | Founder | 63 | 15-09-29 |
| Founder | 65 | 15-09-29 | |
Stefan Abele
CTO | Chief Tech/Sci/R&D Officer | 55 | Nov. 14 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Founder | 65 | 15-09-29 | |
David Meeker
CHM | Chairman | 69 | 20-12-31 |
Robert Glassman
BRD | Director/Board Member | 62 | 20-12-31 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-20 | 20.66 | +1.52% | 33,860 |
| 24-05-17 | 20.35 | -6.26% | 33,049 |
| 24-05-16 | 21.71 | -1.76% | 14,213 |
| 24-05-15 | 22.1 | +6.25% | 60,954 |
| 24-05-14 | 20.8 | -1.75% | 17,452 |
Delayed Quote Nasdaq, May 20, 2024 at 04:00 pm EDT
More quotes
Pharvaris BV is a Switzerland-based clinical-stage company. The activity of the Company focuses on producing oral bradykinin B2-receptor antagonists and is advancing new alternatives to injected therapies for all sub-types of hereditary angioedema (HAE).
Calendar
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
6
Last Close Price
19.02
EUR
Average target price
30.87
EUR
Spread / Average Target
+62.30%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -26.35% | 1.1B | |
| +41.79% | 50.93B | |
| -0.56% | 42.12B | |
| +49.62% | 42.05B | |
| -7.20% | 29.18B | |
| +12.59% | 26.02B | |
| -21.51% | 18.9B | |
| +6.92% | 13.21B | |
| +24.91% | 12.17B | |
| +29.60% | 12.16B |
- Stock Market
- Equities
- PHVS Stock